Human Traumatic Brain Injury Induces Autoantibody Response against Glial Fibrillary Acidic Protein and Its Breakdown Products
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
The role of systemic autoimmunity in human traumatic brain injury (TBI) and other forms of brain injuries is recognized but not well understood. In this study, a systematic investigation was performed to identify serum autoantibody responses to brain-specific proteins after TBI in humans. TBI autoantibodies showed predominant immunoreactivity against a cluster of bands from 38-50 kDa on human brain immunoblots, which were identified as GFAP and GFAP breakdown products. GFAP autoantibody levels increased by 7 days after injury, and were of the IgG subtype predominantly. Results from in vitro tests and rat TBI experiments also indicated that calpain was responsible for removing the amino and carboxyl termini of GFAP to yield a 38 kDa fragment. Additionally, TBI autoantibody staining co-localized with GFAP in injured rat brain and in primary rat astrocytes. These results suggest that GFAP breakdown products persist within degenerating astrocytes in the brain. Anti-GFAP autoantibody also can enter living astroglia cells in culture and its presence appears to compromise glial cell health. TBI patients showed an average 3.77 fold increase in anti-GFAP autoantibody levels from early (0-1 days) to late (7-10 days) times post injury. Changes in autoantibody levels were negatively correlated with outcome as measured by GOS-E score at 6 months, suggesting that TBI patients with greater anti-GFAP immune-responses had worse outcomes. Due to the long lasting nature of IgG, a test to detect anti-GFAP autoantibodies is likely to prolong the temporal window for assessment of brain damage in human patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In that study, the authors did not evaluate the effects of TBI on pituitary function, but they clearly demonstrated that serum levels of glial fibrillary acidic protein autoantibodies increased up to 7 days after the injury.”
From Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach (2015) · cites this paper as [166]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Liu, M. C., Akle, V., Zheng, W., Dave, J. R., Tortella, F. C., Hayes, R. L., & Wang, K. K. W. (2006) · Biochemical Journal · doi:10.1042/bj20050905 · Cited by 86 · cited 1×
“caspases are activated in apoptosis [3,4].”
Self-citationRetractedA Statistical Model for Identifying Proteins by Tandem Mass Spectrometry
Nesvizhskii, A. I., Keller, A., Kolker, E., & Aebersold, R. (2003) · Analytical Chemistry · doi:10.1021/ac0341261 · Cited by 4,809
WILSON, J. T. L., PETTIGREW, L. E. L., & TEASDALE, G. M. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.573 · Cited by 2,386 · cited 1×
“GOS-E) Patient GOS-E scores were assigned to dichotomous ‘‘favorable’’ vs ‘‘unfavorable’’ outcome groups according to recommendations and conventions extensively reported in the literature [33,34].”
BackgroundMiddeldorp, J., & Hol, E. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.01.005 · Cited by 1,080 · cited 1×
“GFAP is an intermediate filament protein specifically localized to the cytoskeleton of mature astrocytes, the most abundant cell type in the central nervous system [32].”
BackgroundCalpain and caspase: can you tell the difference?
Wang, K. K. W. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01479-4 · Cited by 912 · cited 1×
“caspases are activated in apoptosis [3,4].”
Self-citationBlood–brain barrier breakdown as a therapeutic target in traumatic brain injury
Shlosberg, D., Benifla, M., Kaufer, D., & Friedman, A. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.74 · Cited by 897 · cited 1×
“Animal model studies and clinical data both indicate that blood-brain barrier (BBB) breakdown frequently follows head trauma [1,2,5–7].”
BackgroundOrigin and progeny of reactive gliosis: A source of multipotent cells in the injured brain
Buffo, A., Rite, I., Tripathi, P., Lepier, A., Colak, D., Horn, A.-P., Mori, T., & Götz, M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709002105 · Cited by 765 · cited 1×
“In injured brain, astrocytes respond by proliferating and upregulating GFAP in a process termed reactive gliosis [50].”
BackgroundBerger, T., Rubner, P., Schautzer, F., Egg, R., Ulmer, H., Mayringer, I., Dilitz, E., Deisenhammer, F., & Reindl, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022328 · Cited by 616 · cited 1×
“Fro example, measurement of autoantibodies by western blot-based methods might have limited clinical applications [63–65].”
MethodTEASDALE, G. M., PETTIGREW, L. E. L., WILSON, J. T. L., MURRAY, G., & JENNETT, B. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.587 · Cited by 554 · cited 1×
“GOS-E) Patient GOS-E scores were assigned to dichotomous ‘‘favorable’’ vs ‘‘unfavorable’’ outcome groups according to recommendations and conventions extensively reported in the literature [33,34].”
BackgroundPapa, L., Lewis, L. M., Falk, J. L., Zhang, Z., Silvestri, S., Giordano, P., Brophy, G. M., Demery, J. A., Dixit, N. K., Ferguson, I., et al. (2012) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.08.021 · Cited by 332 · cited 1×
“[67] both recently described the GFAP/BDP antigens are detected in serum after mild-moderate TBI.”
BackgroundSelf-citationConsequences of Repeated Blood-Brain Barrier Disruption in Football Players
Marchi, N., Bazarian, J. J., Puvenna, V., Janigro, M., Ghosh, C., Zhong, J., Zhu, T., Blackman, E., Stewart, D., Ellis, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056805 · Cited by 295 · cited 1×
“They further identified a correlation of serum S100B, auto-antibodies and white matter disruption [31].”
BackgroundLack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis
Kuhle, J., Pohl, C., Mehling, M., Edan, G., Freedman, M. S., Hartung, H.-P., Polman, C. H., Miller, D. H., Montalban, X., Barkhof, F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063602 · Cited by 255
Brophy, G. M., Mondello, S., Papa, L., Robicsek, S. A., Gabrielli, A., Tepas, J., Buki, A., Robertson, C., Tortella, F. C., Hayes, R. L., et al. (2011) · Journal of Neurotrauma · doi:10.1089/neu.2010.1564 · Cited by 246 · cited 1×
“breakdown products (SBDPs) [9–13].”
Self-citationCirculating autoantibodies to neuronal and glial filament proteins in autism
Singh, V. K., Warren, R., Averett, R., & Ghaziuddin, M. (1997) · Pediatric Neurology · doi:10.1016/s0887-8994(97)00045-3 · Cited by 234 · cited 1×
“Anti-GFAP autoantibodies have been preliminarily reported in other human disorders, such as in patients with Alzheimer’s disease or other dementias [18,19,52–54], stroke [16,55], diabetes [56], neurological disorders, multiple sclerosis [57,58], autism [59] and leadexposed workers [60].”
BackgroundMondello, S., Papa, L., Buki, A., Bullock, M. R., Czeiter, E., Tortella, F. C., Wang, K. K., & Hayes, R. L. (2011) · Critical Care · doi:10.1186/cc10286 · Cited by 227 · cited 1×
“Because TBI diagnosis currently relies primarily on MRI and/or CT scans and neurological assessments, blood-based biomarker tests would represent a valuable new clinical tool [14].”
BackgroundSelf-citationValidation of Serum Markers for Blood-Brain Barrier Disruption in Traumatic Brain Injury
Blyth, B. J., Farhavar, A., Gee, C., Hawthorn, B., He, H., Nayak, A., Stöcklein, V., & Bazarian, J. J. (2009) · Journal of Neurotrauma · doi:10.1089/neu.2008.0738 · Cited by 226 · cited 1×
“Animal model studies and clinical data both indicate that blood-brain barrier (BBB) breakdown frequently follows head trauma [1,2,5–7].”
BackgroundAutoimmune T cells as potential neuroprotective therapy for spinal cord injury
Hauben, E., Nevo, U., Yoles, E., Moalem, G., Agranov, E., Mor, F., Akselrod, S., Neeman, M., Cohen, I., & Schwartz, M. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05140-5 · Cited by 213 · cited 1×
“Additional studies have reported autoimmune responses in spinal cord injury [21–24].”
BackgroundOkonkwo, D. O., Yue, J. K., Puccio, A. M., Panczykowski, D. M., Inoue, T., McMahon, P. J., Sorani, M. D., Yuh, E. L., Lingsma, H. F., Maas, A. I. R., et al. (2013) · Journal of Neurotrauma · doi:10.1089/neu.2013.2883 · Cited by 210 · cited 1×
“[66] and Papa et al.”
Dambinova, S. A., Khounteev, G. A., Izykenova, G. A., Zavolokov, I. G., Ilyukhina, A. Y., & Skoromets, A. A. (2003) · Clinical Chemistry · doi:10.1373/49.10.1752 · Cited by 207 · cited 1×
“Anti-GFAP autoantibodies have been preliminarily reported in other human disorders, such as in patients with Alzheimer’s disease or other dementias [18,19,52–54], stroke [16,55], diabetes [56], neurological disorders, multiple sclerosis [57,58], autism [59] and leadexposed workers [60].”
BackgroundMondello, S., Robicsek, S. A., Gabrielli, A., Brophy, G. M., Papa, L., Tepas, J., Robertson, C., Buki, A., Scharf, D., Jixiang, M., et al. (2010) · Journal of Neurotrauma · doi:10.1089/neu.2010.1278 · Cited by 204
Self-citationRegional calpain and caspase-3 proteolysis of α-spectrin after traumatic brain injury
Pike, B. R., Zhao, X., Newcomb, J. K., Posmantur, R. M., Wang, K. K., & Hayes, R. L. (1998) · NeuroReport · doi:10.1097/00001756-199808030-00002 · Cited by 204 · cited 1×
“TBI results in activation of calpains as well as caspases, which leads to necrotic and/or apoptotic cell death [11,43–45].”
BackgroundSelf-citationTomkins, O., Feintuch, A., Benifla, M., Cohen, A., Friedman, A., & Shelef, I. (2011) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2011/765923 · Cited by 200
Calpain and caspase: can you tell the difference?, by Kevin K.W. Wang
Wang, K. K. W. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01536-2 · Cited by 194
Self-citationBlood-based diagnostics of traumatic brain injuries
Mondello, S., Muller, U., Jeromin, A., Streeter, J., Hayes, R. L., & Wang, K. K. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.104 · Cited by 186
Self-citationPike, B. R., Flint, J., Dutta, S., Johnson, E., Wang, K. K. W., & Hayes, R. L. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00510.x · Cited by 185 · cited 1×
“TBI results in activation of calpains as well as caspases, which leads to necrotic and/or apoptotic cell death [11,43–45].”
BackgroundSelf-citationAnderson, K. J., Scheff, S. W., Miller, K. M., Roberts, K. N., Gilmer, L. K., Yang, C., & Shaw, G. (2008) · Journal of Neurotrauma · doi:10.1089/neu.2007.0488 · Cited by 180 · cited 1×
“breakdown products (SBDPs) [9–13].”
Glial Fibrillary Acidic Protein is Highly Correlated With Brain Injury
Lumpkins, K. M., Bochicchio, G. V., Keledjian, K., Simard, J. M., McCunn, M., & Scalea, T. (2008) · Journal of Trauma: Injury, Infection & Critical Care · doi:10.1097/ta.0b013e318185db2d · Cited by 169 · cited 1×
“While levels of released GFAP decline rapidly after TBI [48,68], IgG-based autoantibodies could potentially last for days to months.”
BackgroundUbiquitin C‐terminal hydrolase‐L1 as a biomarker for ischemic and traumatic brain injury in rats
Liu, M. C., Akinyi, L., Scharf, D., Mo, J., Larner, S. F., Muller, U., Oli, M. W., Zheng, W., Kobeissy, F. H., Papa, L., et al. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07097.x · Cited by 168 · cited 1×
“Similarly, cortex was examined from rats subjected to controlled cortical impact (CCI) injury [46].”
MethodSelf-citationMartínez, J. A., Zhang, Z., Svetlov, S. I., Hayes, R. L., Wang, K., & Larner, S. F. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0526-4 · Cited by 157 · cited 1×
“Cells were pretreated with either the calpain inhibitor SNJ, or the pan-caspase inhibitor Z-VAD-FMK for 1 h before drug challenges as described [40].”
MethodSelf-citationA Panel of Neuron-Enriched Proteins as Markers for Traumatic Brain Injury in Humans
Siman, R. G., Toraskar, N., Dang, A., McNeil, E. M., McGarvey, M., Plaum, J., Maloney, E., & Grady, M. S. (2009) · Journal of Neurotrauma · doi:10.1089/neu.2009.0882 · Cited by 156 · cited 1×
“breakdown products (SBDPs) [9–13].”
Tanriverdi, F., De Bellis, A., Bizzarro, A., Sinisi, A. A., Bellastella, G., Pane, E., Bellastella, A., Unluhizarci, K., Selcuklu, A., Casanueva, F. F., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0050 · Cited by 153 · cited 1×
“also identified the presence of anti-pituitary antibodies in patient serum 3 years after head trauma [29,30].”
BackgroundMondello, S., Jeromin, A., Buki, A., Bullock, R., Czeiter, E., Kovacs, N., Barzo, P., Schmid, K., Tortella, F., Wang, K. K., et al. (2012) · Journal of Neurotrauma · doi:10.1089/neu.2011.2092 · Cited by 137 · cited 2×
“While levels of released GFAP decline rapidly after TBI [48,68], IgG-based autoantibodies could potentially last for days to months.”
BackgroundSelf-citationNETs: the missing link between cell death and systemic autoimmune diseases?
Darrah, E., & Andrade, F. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00428 · Cited by 133
Zhang, Z., Larner, S. F., Liu, M. C., Zheng, W., Hayes, R. L., & Wang, K. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0405-z · Cited by 132 · cited 6×
“MTX was used at 3 nM for 3 h, and EDTA was used at 5 mM for 24 h [39].”
BackgroundMethodSelf-citationLevin, E. C., Acharya, N. K., Han, M. C., Zavareh, S., Sedeyn, J. C., Venkataraman, V., & Nagele, R. G. (2010) · Brain Research · doi:10.1016/j.brainres.2010.05.038 · Cited by 128
Williams, A. J., Hartings, J. A., Lu, X.-C. M., Rolli, M. L., & Tortella, F. C. (2006) · Journal of Neurotrauma · doi:10.1089/neu.2006.23.1828 · Cited by 124 · cited 2×
“First, a rat model of experimental penetrating ballistic-like brain injury (PBBI) was used [1].”
BackgroundMethodSelf-citationB cells and autoantibodies: Complex roles in CNS injury
Ankeny, D. P., & Popovich, P. G. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.06.006 · Cited by 116 · cited 1×
“Additional studies have reported autoimmune responses in spinal cord injury [21–24].”
BackgroundAdd Alzheimer's disease to the list of autoimmune diseases
D’Andrea, M. R. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2004.08.024 · Cited by 113
Brophy, G. M., Pineda, J., Papa, L., Lewis, S. B., Valadka, A. B., Hannay, H. J., Heaton, S. C., Demery, J. A., Liu, M. C., Tepas, J. J., et al. (2009) · Journal of Neurotrauma · doi:10.1089/neu.2008.0657 · Cited by 108
Self-citationTanriverdi, F., De Bellis, A., Battaglia, M., Bellastella, G., Bizzarro, A., Sinisi, A. A., Bellastella, A., Unluhizarci, K., Selcuklu, A., Casanueva, F. F., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-1024 · Cited by 108 · cited 1×
“also identified the presence of anti-pituitary antibodies in patient serum 3 years after head trauma [29,30].”
BackgroundNew autoantibody mediated disorders of the central nervous system
Lang, B., Dale, R. C., & Vincent, A. C. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200306000-00016 · Cited by 87
Regulation of CD14 expression on human adult central nervous system-derived microglia
Becher, B., Fedorowicz, V., & Antel, J. P. (1996) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19960815)45:4<375::aid-jnr6>3.0.co;2-6 · Cited by 85
Mecocci, P., Parnetti, L., Romano, G., Scarelli, A., Chionne, F., Cecchetti, R., Polidori, M. C., Palumbo, B., Cherubini, A., & Senin, U. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(94)00180-v · Cited by 75 · cited 1×
“Anti-GFAP autoantibodies have been preliminarily reported in other human disorders, such as in patients with Alzheimer’s disease or other dementias [18,19,52–54], stroke [16,55], diabetes [56], neurological disorders, multiple sclerosis [57,58], autism [59] and leadexposed workers [60].”
BackgroundHedegaard, C. J., Chen, N., Sellebjerg, F., Sørensen, P. S., Leslie, R. G. Q., Bendtzen, K., & Nielsen, C. H. (2009) · Immunology · doi:10.1111/j.1365-2567.2008.02999.x · Cited by 71 · cited 1×
“In human TBI, however, autoimmunity has only been examined in a limited way and focused on autoantibodies against preselected antigens such as MBP, S100B, and glutamate receptors [15,25–28].”
BackgroundWilliams, A. J., Ling, G. S. F., & Tortella, F. C. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.08.086 · Cited by 68 · cited 1×
“5% of total rat brain volume [35].”
Self-citationCharacterization of Antibodies that Detect Human GFAP after Traumatic Brain Injury
Zoltewicz, J. S., Scharf, D., Yang, B., Chawla, A., Newsom, K. J., & Fang, L. (2012) · Biomarker Insights · doi:10.4137/bmi.s9873 · Cited by 65 · cited 3×
“Calpain-2 and caspase-3 in vitro digestions of rat brain lysates were performed as described [36,37].”
BackgroundMethodSelf-citationColasanti, T., Barbati, C., Rosano, G. M. C., Malorni, W., & Ortona, E. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.07.008 · Cited by 65 · cited 2×
“Anti-GFAP autoantibodies have been preliminarily reported in other human disorders, such as in patients with Alzheimer’s disease or other dementias [18,19,52–54], stroke [16,55], diabetes [56], neurological disorders, multiple sclerosis [57,58], autism [59] and leadexposed workers [60].”
BackgroundBiomarkers Track Damage after Graded Injury Severity in a Rat Model of Penetrating Brain Injury
Zoltewicz, J. S., Mondello, S., Yang, B., Newsom, K. J., Kobeissy, F., Yao, C., Lu, X.-C. M., Dave, J. R., Shear, D. A., Schmid, K., et al. (2013) · Journal of Neurotrauma · doi:10.1089/neu.2012.2762 · Cited by 62 · cited 7×
“First, a rat model of experimental penetrating ballistic-like brain injury (PBBI) was used [1].”
BackgroundSelf-citationLiu, M. C., Kobeissy, F., Zheng, W., Zhang, Z., Hayes, R. L., & Wang, K. K. W. (2011) · ASN Neuro · doi:10.1042/an20100012 · Cited by 58 · cited 4×
“Calpain-2 and caspase-3 in vitro digestions of rat brain lysates were performed as described [36,37].”
MethodSelf-citationAntimyelin Antibodies with No Progression to Multiple Sclerosis
Pelayo, R., Tintoré, M., Montalbán, X., Rovira, À., Espejo, C., Reindl, M., & Berger, T. (2007) · New England Journal of Medicine · doi:10.1056/nejmc062467 · Cited by 57 · cited 1×
“Fro example, measurement of autoantibodies by western blot-based methods might have limited clinical applications [63–65].”
MethodAn investigation of auto-reactivity after head injury
Cox, A. L., Coles, A. J., Nortje, J., Bradley, P. G., Chatfield, D. A., Thompson, S., & Menon, D. K. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.01.007 · Cited by 57 · cited 1×
“In human TBI, however, autoimmunity has only been examined in a limited way and focused on autoantibodies against preselected antigens such as MBP, S100B, and glutamate receptors [15,25–28].”
BackgroundPonomarenko, N. A., Durova, O. M., Vorobiev, I. I., Belogurov, A. A., Telegin, G. B., Suchkov, S. V., Misikov, V. K., Morse, H. C., & Gabibov, A. G. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.10.006 · Cited by 51 · cited 3×
“Patients with MS develop circulating autoantibodies against MBP [15].”
BackgroundIn vivo cell penetration and intracellular transport of anti-Sm and anti-La autoantibodies
Deng, S. X., Hanson, E. M., & Sanz, I. (2000) · International Immunology · doi:10.1093/intimm/12.4.415 · Cited by 50 · cited 1×
“This is consistent with previous work showing that anti-nuclear autoantibodies can also enter cells [49].”
ResultSerum GFAP autoantibody as an ELISA-detectable glioma marker
Wei, P., Zhang, W., Yang, L., Zhang, H.-S., Xu, X., Jiang, Y.-H., Huang, F., & Shi, Q. (2013) · Tumor Biology · doi:10.1007/s13277-013-0770-7 · Cited by 45 · cited 1×
“reported [61].”
Tanaka, J., Nakamura, K., Takeda, M., Tada, K., Suzuki, H., Morita, H., Okado, T., Hariguchi, S., & Nishimura, T. (1989) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1989.tb03926.x · Cited by 45 · cited 1×
“Anti-GFAP autoantibodies have been preliminarily reported in other human disorders, such as in patients with Alzheimer’s disease or other dementias [18,19,52–54], stroke [16,55], diabetes [56], neurological disorders, multiple sclerosis [57,58], autism [59] and leadexposed workers [60].”
BackgroundPoletaev, A. B., Morozov, S., Gnedenko, B. B., Zlunikin, V. M., & Korzhenevskey, D. A. (2000) · Autoimmunity · doi:10.3109/08916930008995985 · Cited by 44
Guingab‐Cagmat, J. D., Newsom, K., Vakulenko, A., Cagmat, E. B., Kobeissy, F. H., Zoltewicz, S., Wang, K. K., & Anagli, J. (2012) · ELECTROPHORESIS · doi:10.1002/elps.201200326 · Cited by 37 · cited 1×
“Our previous reports state that GFAP in fact is vulnerable to proteolytic processing linked to calpain activation [41,42].”
BackgroundSelf-citationGlutamate receptor autoantibody concentrations in children with chronic post-traumatic headache
Goryunova, A. V., Bazarnaia, N. A., Sorokina, E. G., Semenova, N., Globa, O. V., Семенова, Ж. Б., Pinelis, V. G., Roshal, L. M., & Маслова, О. И. (2007) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-007-0079-3 · Cited by 37 · cited 1×
“In human TBI, however, autoimmunity has only been examined in a limited way and focused on autoantibodies against preselected antigens such as MBP, S100B, and glutamate receptors [15,25–28].”
BackgroundProtein Biomarkers for Traumatic and Ischemic Brain Injury: From Bench to Bedside
Zhang, Z., Mondello, S., Kobeissy, F. H., Rubenstein, R., Streeter, J., Hayes, R. L., & Wang, K. (2011) · Translational Stroke Research · doi:10.1007/s12975-011-0137-6 · Cited by 36 · cited 1×
“and blood [2–4,8].”
Self-citationFujita, K., Kato, T., Yamauchi, M., Ando, M., Honda, M., & Nagata, Y. (1998) · Neurochemical Research · doi:10.1023/a:1022476724381 · Cited by 32 · cited 1×
“GFAP [47].”
Chapter 29 T cell-based therapeutic vaccination for spinal cord injury
Schwartz, M., & Hauben, E. (2002) · Progress in brain research · doi:10.1016/s0079-6123(02)37031-6 · Cited by 31 · cited 1×
“Additional studies have reported autoimmune responses in spinal cord injury [21–24].”
BackgroundDambinova, S. A., Izykenova, G. A., Burov, S. V., Grigorenko, E. V., & Gromov, S. A. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00150-0 · Cited by 27 · cited 1×
“Reports have documented brain-directed autoimmunity in neurological and neurodegenerative diseases such as Alzheimer’s disease, stroke, epilepsy, and paraneoplastic syndromes [16–20].”
Backgroundβ2-glycoprotein I and annexin A5 phospholipid interactions: Artificial and cell membranes
Frank‐Bertoncelj, M., Sodin‐Šemrl, S., Irman, Š., Božič, B., & Rozman, B. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.02.025 · Cited by 25
Autoantibodies to glial fibrillary acid protein and S100β in diabetic patients
Gomez-Touriño, I. M., Camiña-Darriba, F., Otero‐Romero, I., Rodríguez, M. A., Hernández‐Fernández, A., González‐Fernández, Á., González, E. P., Rodríguez, J., Rodríguez‐Segade, S., & Varela‐Calviño, R. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02911.x · Cited by 23
Serum autoantibodies against glial fibrillary acidic protein in brain aging and senile dementias
Mecocci, P., Parnetti, L., Donato, R., Santucci, C., Santucci, A., Cadini, D., Foa', E., Cecchetti, R., & Senin, U. (1992) · Brain Behavior and Immunity · doi:10.1016/0889-1591(92)90049-t · Cited by 22
Sorokina, E. G., Семенова, Ж. Б., Granstrem, O., Karaseva, O. V., Мещеряков, С. В., Reutov, V. P., Сушкевич, Г. Н., Pinelis, V. G., & Roshal, L. M. (2010) · PubMed · Cited by 16
Abdel-Moneim, I., SHAMY, M. Y., El-Gazzar, R., & El‐Fawal, H. A. N. (1999) · PubMed · Cited by 12
[Neurospecific proteins and autoantibodies in serum of patients with acute ischemic stroke].
Pr, K., Ruleva, N. I., Дугин, С. Ф., Li, B., Chugunov, A. V., Mikhaĭlova, N. A., & Бассэ, Д. А. (2009) · PubMed · Cited by 8
Górny, M. K., Losy, J., & Wender, M. (1992) · PubMed · Cited by 8
Recent MRI Advances in Experimental Stroke
Duong, T. Q. (2012) · Translational Stroke Research · doi:10.1007/s12975-012-0144-2 · Cited by 4
Cited by
Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research
Maas, A. I. R., Menon, D. K., Adelson, P. D., Andelic, N., Bell, M. J., Belli, A., Bragge, P., Brazinova, A., Büki, A., Chesnut, R. M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30371-x · Cited by 2,609
Self-citationThe far-reaching scope of neuroinflammation after traumatic brain injury
Simon, D. W., McGeachy, M. J., Bayır, H., Clark, R. S. B., Loane, D. J., & Kochanek, P. M. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.13 · Cited by 1,190
Glial fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker
Yang, Z., & Wang, K. K. W. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.04.003 · Cited by 1,050
Self-citationBlood GFAP as an emerging biomarker in brain and spinal cord disorders
Abdelhak, A., Foschi, M., Abu-Rumeileh, S., Yue, J. K., D’Anna, L., Huss, A., Oeckl, P., Ludolph, A. C., Kuhle, J., Petzold, A., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00616-3 · Cited by 807
Flanagan, E. P., Hinson, S. R., Lennon, V. A., Fang, B., Aksamit, A. J., Morris, P. P., Basal, E., Honorat, J. A., Alfugham, N. B., Linnoila, J. J., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24881 · Cited by 550
“Encephalitis 43 (42) 18 of 33 (55) 34 of 36 (94) 7 (16) 19 (44) 5 of 7 (71)”
Metadata
- Authors
- Zhang, Z., Zoltewicz, J. S., Mondello, S., Newsom, K. J., Yang, Z., Yang, B., Kobeissy, F., Guingab, J., Glushakova, O., Robicsek, S., Heaton, S., Buki, A., Hannay, J., Gold, M. S., Rubenstein, R., Lu, X.-C. M., Dave, J. R., Schmid, K., Tortella, F., Robertson, C. S., & Wang, K. K. W.
- Affiliations
- Banyan Biomarkers (United States) (US)
- University of Florida (US)
- University of Messina (IT)
- University of Florida Health (US)
- SUNY Downstate Health Sciences University (US)
- Walter Reed Army Institute of Research (US)
- Baylor College of Medicine (US)
- Corresponding author
- Zhang, Zhiqun
- Zoltewicz, J. Susie
- Wang, Kevin K. W.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-03-25
- Volume
- 9
- Issue
- 3
- Pages
- e92698
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3965455
- OpenAlex
- W2085281517
- Semantic Scholar
- e80c01fdab639dbf4a2efbc9669e9615dbac4901
- Cited by
- 200
- References
- 70
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 18 · 2023: 13 · 2022: 21 · 2021: 20 · 2020: 19 · 2019: 15 · 2018: 11 · 2017: 20 · 2016: 13 · 2015: 22 · 2014: 5
- FWCI
- 13.04
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-06-25)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- U.S. Department of Defense (DAMD170310772)
- University of Pittsburgh
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS051431, R01NS052831, R01NS049175)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury and Neurovascular Disturbances
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
- Health Sciences › Medicine › Clinical Neurology › Spinal Cord Injury Research
- Keywords
- traumatic brain injury, autoantibodies, glial fibrillary acidic protein, calpain, astrocytes, systemic autoimmunity, IgG, brain damage biomarkers, functional outcome, rat model
- MeSH terms
- Adult, Animals, Astrocytes, Autoantibodies, Brain Injuries, Female, Glial Fibrillary Acidic Protein, Humans, Immunoglobulin G, Male, Time Factors, Rats, Sprague-Dawley, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.